BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 10556213)

  • 1. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
    Sun Q; Pollok KE; Burton RL; Dai LJ; Britt W; Emanuel DJ; Lucas KG
    Blood; 1999 Nov; 94(9):3242-50. PubMed ID: 10556213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B lymphoblastoid cell lines as efficient APC to elicit CD8+ T cell responses against a cytomegalovirus antigen.
    Sun Q; Burton RL; Dai LJ; Britt WJ; Lucas KG
    J Immunol; 2000 Oct; 165(7):4105-11. PubMed ID: 11034422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens.
    Karlsson H; Brewin J; Kinnon C; Veys P; Amrolia PJ
    J Immunother; 2007; 30(5):544-56. PubMed ID: 17589295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.
    Moosmann A; Khan N; Cobbold M; Zentz C; Delecluse HJ; Hollweck G; Hislop AD; Blake NW; Croom-Carter D; Wollenberg B; Moss PA; Zeidler R; Rickinson AB; Hammerschmidt W
    Blood; 2002 Sep; 100(5):1755-64. PubMed ID: 12176897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.
    Hanley PJ; Shaffer DR; Cruz CR; Ku S; Tzou B; Liu H; Demmler-Harrison G; Heslop HE; Rooney CM; Gottschalk S; Bollard CM
    Cytotherapy; 2011 Sep; 13(8):976-86. PubMed ID: 21539497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells.
    Keever-Taylor CA; Margolis D; Konings S; Sandford GR; Nicolette CA; Lawendowski C; Burns WH
    Biol Blood Marrow Transplant; 2001; 7(5):247-56. PubMed ID: 11400946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
    Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
    J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ex vivo inducing cultured Epstein-Barr virus specific cytotoxic T lymphocytes and evaluation of their killing effect].
    Chen GH; Gu B; Chen F; Wang Y; Qiao M; Liu HW; Feng YF; Dai LJ; Zhu ZL; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1597-601. PubMed ID: 24370055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles.
    Kondo E; Akatsuka Y; Kuzushima K; Tsujimura K; Asakura S; Tajima K; Kagami Y; Kodera Y; Tanimoto M; Morishima Y; Takahashi T
    Blood; 2004 Jan; 103(2):630-8. PubMed ID: 12947002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals.
    Ventura C; Bisceglia H; Girerd-Chambaz Y; Burdin N; Chaux P
    J Clin Immunol; 2012 Dec; 32(6):1305-16. PubMed ID: 22797815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
    Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
    Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines.
    Wiesner M; Zentz C; Hammer MH; Cobbold M; Kern F; Kolb HJ; Hammerschmidt W; Zeidler R; Moosmann A
    Eur J Immunol; 2005 Jul; 35(7):2110-21. PubMed ID: 15971271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.
    Lacey SF; Gallez-Hawkins G; Crooks M; Martinez J; Senitzer D; Forman SJ; Spielberger R; Zaia JA; Diamond DJ
    Transplantation; 2002 Sep; 74(5):722-32. PubMed ID: 12352893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses.
    Zhu F; Ramadan G; Davies B; Margolis DA; Keever-Taylor CA
    Clin Exp Immunol; 2008 Feb; 151(2):284-96. PubMed ID: 18005260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.
    Sili U; Leen AM; Vera JF; Gee AP; Huls H; Heslop HE; Bollard CM; Rooney CM
    Cytotherapy; 2012 Jan; 14(1):7-11. PubMed ID: 22172091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
    Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.